Listar por autor "Domingo, Pere"
-
Massanella, Marta; Ouchi, Dan; Marfil, Sílvia; Llibre, Josep M.; Puertas, M.C.; Buzon, Maria J.; Richman, Douglas D.; Orna, Elisa; Stevenson, Mario; Gatell, J.M.; Domingo, Pere; Negredo, Eugenia; Martinez Picado, Francisco Javier; Clotet, Bonaventura; Blanco, Julià
(Public Library of Science, 2014)
Abstract
Background
HIV-1 infection increases plasma levels of inflammatory markers. Combination antiretroviral therapy (cART) does not restore inflammatory markers to normal levels. Since intensification of cART ...
-
Echeverria, Patricia; Domingo, Pere; Llibre, Josep M.; Gutierrez, Mar; Mateo, Gracia; Puig, Jordi; Bonjoch, Anna; Pérez Alvarez, Núria; Sirera, Guillem; Clotet, Bonaventura; Negredo, Eugenia
(Hindawi Publishing Corporation, 2014)
There are conflicting data on the prevalence of coronary events and the quality of the management of modifiable
cardiovascular risk factors (CVRF) inHIV-infected patients. Methods.We performed a retrospective descriptive ...
-
Moltó, José; Valle, Marta; Ferrer, Elena; Domingo, Pere; Curran, Adrian; Santos, José R.; Di Yacovo, María Silvana; Miranda, Cristina; Podzamczer Palter, Daniel; Clotet, Bonaventura
(Oxford University Press, 2015)
Objectives: Maximizing ART efficiency is of growing interest. This study assessed the efficacy, safety,
pharmacokinetics and economics of a darunavir dose-reduction strategy.
Methods: This was a multicentre, randomized, ...
-
Negredo, Eugenia; Diez-Pérez, Adolfo; Bonjoch, Anna; Domingo, Pere; Pérez Alvarez, Núria; Gutierrez, Mar; Mateo, Gracia; Puig, Jordi; Echeverria, Patricia; Escrig, R.; Clotet, Bonaventura
(Oxford University Press, 2015)
Background: Tenofovir is involved in accelerated bone mineral density (BMD) loss.
Methods: We recently published a hip BMD improvement at week 48 [+2.1% (95% CI: 20.6, 4.7) (P¼0.043)] in
HIV-infected patients with ...